Sirona Dx recognized as a Top 10 CRO of 2021 by Medhealth Outlook
The development of innovative immunotherapy approaches for cancers and autoimmune disorders among others, remains a top priority for Biopharma however numerous challenges create hurdles to progress. To begin with, there is a requirement for multi-faceted, high-parameter, single cell readouts from limited sample inputs to identify informative biomarker signatures. Furthermore, the complex nature of the underlying […]
Sirona Dx presents at Fluidigm Virtual Mass Cytometry Investor Day
Dr. Nasry Yassa, CEO and Andrew Brown, Chief Commercial Officer, discuss the use of Fluidigm Mass Cytometry technology within their specialty contract research organization. They have created a specialized CRO business that partners with biopharma to accelerate drug development work, with a focus on introducing novel technologies into early clinical stage development. At this event […]
Sirona Dx Launches Rapid Saliva Based PCR COVID-19 Testing Service Utilizing Advanced Microfluidics
We have implemented advanced microfluidics technology to enable rapid, accurate, lower cost COVID-19 testing on easy to collect saliva samples. The Advanta™ SARS-CoV-2 RT-PCR assay was developed by Fluidigm and is supported by an EUA. The assay is a reverse transcription and real-time polymerase chain reaction (RT-PCR) test that leverages Fluidigm microfluidics technology with the […]
Customer Spotlight: Supporting Drug Discovery & Development with CODEX
Sirona Dx is a Portland, Oregon-based technical contract research organization (CRO), which provides high-complexity genomics and proteomics services to pharmaceutical and biotech companies to support drug discovery and development in immuno-oncology. Sirona Dx recently brought the CODEX platform on board to support discovery research with single-cell, spatially resolved multiplex imaging. To learn how the CRO is accelerating […]
Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore., Nov. 01, 2018 (GLOBE NEWSWIRE) — Sirona Dx, a leader in high-complexity genomics and proteomics services, today announced the introduction of Imaging Mass Cytometry™ services on the Fluidigm Hyperion™ Imaging System to advance biomarker discovery and […]
About Sirona Dx
Sirona Dx is a CLIA accredited technical CRO, founded to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between life science tools developers and translational clinical research, our laboratory offers specialized high complexity single cell proteomics and genomics services to support drug discovery and development programs.
Ultivue Announces Co-Marketing Agreement with Sirona Dx for Multiplexed Tissue Biomarker Solutions
Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine CAMBRIDGE, Mass. & PORTLAND, Ore.–(BUSINESS WIRE)–Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Sirona Dx, a technical contract research organization (CRO), providing advanced, single cell proteomics and genomics services to […]